Download Errata - Blood Journal

From www.bloodjournal.org by guest on June 18, 2017. For personal use only.
Errata
Franchini and Lippi. Acquired factor VIII inhibitors. Blood. 2008;112:250-255.
On page 253 in the July 15, 2008, How I treat article under the
heading “High-dose intravenous immunoglobulin,” the dosage of
intravenous immunoglobulin (IVIG) reported in the penultimate
sentence of the paragraph, 2 g/kg for 2 days, is incorrect. The
correct dose is 1 g/kg for 2 days, as reported in Table 2 on page 251
of the article.
Tjwa et al. Plasmin therapy enhances mobilization of HPCs after G-CSF. Blood. 2008;112:40484050.
On page 4049 in the November 15, 2008, issue, the second and
third sentences of the second paragraph under the heading “Thrombolytic agents enhance HPC mobilization after G-CSF” contain
incorrect information.
The correct sentences should read: “Nonetheless, daily intraperitoneal bolus injection of human rtPA (100 mg/kg) for 5 days failed to
enhance HPC mobilization or increase leukocytosis in steady-state
conditions or following G-CSF administration in mice (not shown).
Heissig et al reported that a 10-fold lower dose of human rtPA in mice
increases leukocytosis after myeloablation10; the precise reason for this
variance remains unexplained, but might be related to the different
experimental conditions (G-CSF versus myeloablation).”
Inomata et al. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell
lymphoma subtypes. Blood. 2009;113:396-402.
On pages 399 and 400 in the January 8, 2009, issue, there were 3
errors.
In Figure 3B, the label that reads “Raji-m2” for the third black
bar in both graphs is incorrect. The label should read “Raji-m1.”
On page 400 under the heading “Effects of ASOs in Jeko-1 cells
reveal that p21 is an essential target of the miR-17-92 polycistron
during lymphomagenesis,” the fourth sentence is incorrect.
TP53INP1 should not have appeared in the sentence. The correct
sentence should read: “RQ-PCR analysis of CDKN1A expression
in Jeko-1 cells treated with ASOs or SCOs revealed that although
there was no significant difference between expression levels in
cells treated with AS-19 or SC-19, cells treated with AS-17, with or
without AS-20, showed greater expression than cells treated with
the respective SCOs (Figure 5B).”
The legend for Figure 4 is incorrect. In the second sentence,
reference to miR-17 expression and SUDHL4 cells is incorrect.
The last sentence is missing the word “as.” The correct figure
legend follows:
Figure 4. Jeko-1 cells show both miR-17–92 overexpression
and homozygous deletion of BIM. (A) Northern blot analysis of
miR-19 and miR-20a expression in 4 B-cell lymphoma cell lines:
lane 1 represents Jeko-1; lane 2, SP49; lane 3, SUDHL4; and lane
4, Raji. Fold changes in miR-19a and 20a expressions are shown
below the gels and normalized to the level in Jeko-1 cells, which
was assigned a value of 1.00. (B) Top panels: Southern blot
analysis (SB) of the BIM locus carried out using genomic DNA,
including BIM, from the 4 indicated cell lines. Bottom panels:
Northern blot analysis (NB) of BIM, from the 4 indicated cell lines.
A cDNA fragment of ␤-actin was used as a control.
Goldenberg et al. Properties and structure-function relationships of veltuzumab (hA20), a
humanized anti-CD20 monoclonal antibody. Blood. 2009;113:1062-1070.
On page 1063 in the January 29, 2009, issue, there is an error in
Table 1. The letter “Y” representing amino acid 102 should have
5368
appeared in the bottom row (1F5) of the last column (102).
BLOOD, 21 MAY 2009 䡠 VOLUME 113, NUMBER 21
From www.bloodjournal.org by guest on June 18, 2017. For personal use only.
2009 113: 5368
doi:10.1182/blood-2008-10-186270
Franchini and Lippi. Acquired factor VIII inhibitors. Blood.
2008;112:250-255.
Updated information and services can be found at:
http://www.bloodjournal.org/content/113/21/5368.1.full.html
Articles on similar topics can be found in the following Blood collections
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Copyright 2011 by The American Society of Hematology; all rights reserved.